We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization’s COVAX program are launching a “marketplace” to make use of unused materials and idle stock to increase the global production of COVID-19 vaccines for underserved populations. Read More
Mount Sinai Hospital in New York and Cleveland Clinic are the latest large players in healthcare to flash a red light at Biogen’s controversial new Alzheimer’s drug Aduhelm. Read More
Teva Pharmaceuticals has sued Amicus Therapeutics, alleging the company refused to supply samples of its high-priced branded drug, Galafold (migalastat), as required under federal law. Read More
AstraZeneca’s acquisition of Boston-based Alexion Pharmaceuticals has been cleared by the UK’s Competition and Markets Authority — passing the final hurdle that will allow the $39 billion deal to close next week. Read More
Rounding out its holdings in the diabetes space, Eli Lilly has bought the remaining shares of biotech Protomer Technologies, which has a peptide- and protein-engineering platform that can identify and synthesize molecules that sense glucose. Read More
Drug wholesalers’ claims that Eli Lilly, Sanofi, Novo Nordisk and a group of pharmacy benefit managers (PBMs) engaged in racketeering can proceed, said a federal judge, who at the same time dismissed antitrust allegations that the companies worked together to overcharge for diabetes drugs. Read More
The FDA’s approval of Biogen’s Aduhelm for treatment of Alzheimer’s disease (AD) has taken regulators, payers and patients to an unprecedented intersection of medical need, clinical benefit and cost. Read More